1 Tower Place, Suite 300
South San Francisco, CA 94080-7603
Biotech and Pharmaceutical
Achaogen (a-KAY-o-jen) develops small molecule therapeutics to treat multi-drug resistant bacterial infections, a serious unmet medical need causing hundreds of thousands of deaths worldwide each year. Achaogen is developing next-generation aminoglycosides. Our lead compounds display broad-spectrum activity against many resistant bacteria that cause systemic infections, including K. pneumoniae, E. coli and MRSA.